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Abstract
Background
HIV suppression at parturition is beneficial for maternal, fetal and public health. To eliminate
mother-to-child transmission of HIV, an understanding of missed opportunities for antiretro-
viral therapy (ART) use during pregnancy and HIV suppression at delivery is required.
Methodology
We performed a retrospective analysis of 836 mother-to-child pairs involving 656 HIV-
infected women in Philadelphia, 2005-2013. Multivariable regression examined associa-
tions between patient (age, race/ethnicity, insurance status, drug use) and clinical factors
such as adequacy of prenatal care measured by the Kessner index which classifies prenatal
care as inadequate, intermediate, or adequate prenatal care; timing of HIV diagnosis; and
the outcomes: receipt of ART during pregnancy and viral suppression at delivery.
Results
Overall, 25% of the sample was diagnosed with HIV during pregnancy; 39%, 38%, and 23%
were adequately, intermediately, and inadequately engaged in prenatal care. Eight-five per-
cent of mother-to-child pairs received ART during pregnancy but only 52% achieved sup-
pression at delivery. Adjusting for patient factors, pairs diagnosed with HIV during
pregnancy were less likely to receive ART (AOR 0.39, 95% CI 0.25-0.61) and achieve viral
suppression (AOR 0.70, 95% CI 0.49-1.00) than those diagnosed before pregnancy. Simi-
larly, women with inadequate prenatal care were less likely to receive ART (AOR 0.06, 95%
CI 0.03-0.11) and achieve viral suppression (AOR 0.31, 95% CI 0.20-0.47) than those with
adequate prenatal care.
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Conclusions
Targeted interventions to diagnose HIV prior to pregnancy and engage HIV-infected
women in prenatal care have the potential to improve HIV related outcomes in the perinatal
period.
Introduction
HIV viral suppression during pregnancy and at the time of delivery is crucial to preventing
mother to child transmission (MTCT) of HIV.[1–4] Among untreated mothers, 70% of HIV
transmissions occur during labor and delivery, [5, 6] which represent a critical window period
where interventions to optimize viral suppression are essential. In the U.S., public health rec-
ommendations to prevent MTCT of HIV include: (1) universal HIV screening during the first
trimester, (2) use of combination antiretroviral therapy (ART) among all HIV-infected preg-
nant women regardless of viral load (VL) or CD4 count, (3) delivery via scheduled Caesarean
section when maternal VL is>1,000 copies/ml, and (4) post-exposure prophylaxis for all HIV-
exposed infants.[7, 8] Implementation of these recommendations have successfully reduced
the incidence of HIV vertical transmission in the U.S. from 22% in the pre-ART era[4] to 2%
in the modern ART era[9]. Despite this success, MTCT persists and is particularly elevated
among ethnic minorities.[10] There are approximately 278,000 women age 13 or older living
with HIV in the US and the number of women with HIV giving birth has increased 30% more
from 6,000 in 2000 to 8,700 in 2006.[10] These findings suggest that additional efforts are
needed to optimize maternal HIV care in order to prevent vertical transmission of HIV and
reach the goal of<1%MTCT rate established by the Centers for Disease Control (CDC)[11].
The benefits of viral suppression during pregnancy go beyond the reduction of MTCT; the
impact of uncontrolled HIV disease has direct implications on women and fetal health and
increases the economic burden on communities. Uncontrolled viral replication and ART non-
adherence lead to viral resistance, AIDS, and is associated with a higher risk of HIV transmis-
sion. Vis-à-vis the infant, fetal health is directly linked to maternal health. Studies show that
uninfected but HIV-exposed infants born to HIV-infected mothers have higher rates of mor-
tality than do infants born to uninfected mothers, and infant mortality is associated with
advanced maternal HIV disease.[12–14] Data from 7,638 HIV exposed but uninfected infants
in France show a 60% increase risk of serious bacterial infection when maternal CD4 is<350
cells/mm3.[15] Quantitative and qualitative immunological studies have demonstrated that
impaired maternal humoral immunity, which is passively transferred through the placenta,
result in reduced infant CD4/CD8,[16] naïve or memory T cells,[16, 17] cytokine production
and increased T cell apoptosis.[16, 18]
Use of ART and HIV viral suppression during pregnancy are achievable goals since many
pregnant women are motivated to take ART to minimize the risk of MTCT.[19, 20] As such,
early HIV diagnosis and engagement in prenatal care are modifiable factors that have the
potential of improving viral suppression at delivery. To ensure that HIV-infected pregnant
women receive all available HIV prevention services, public health authorities need to under-
stand factors associated with missed opportunities of ART receipt during pregnancy and viral
suppression at delivery. Our aim was to evaluate how timing of HIV diagnosis and engagement
in prenatal care are associated with receipt of ART during pregnancy and viral suppression at
delivery. We hypothesized that women diagnosed with HIV during pregnancy and those with
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inadequate engagement in prenatal care would be less likely to receive ART during pregnancy
and less likely to be suppressed at delivery.
Materials and Methods
Study Population
The Enhanced Perinatal Surveillance (EPS) project is a population-based surveillance system
of HIV-infected pregnant women in 15 high incidence areas, including 9 U.S. states, 5 U.S. cit-
ies, and Puerto Rico. The overarching goals of EPS are to assist public health officials in timely
evaluation of perinatal HIV prevention efforts and assess the use of ART among HIV-infected
pregnant women. Mother and infant pairs are identified through comprehensive epidemiologic
surveillance methods described elsewhere.[21] In brief, mother and infant pairs are identified
through the pediatric HIV surveillance system, laboratory reporting, reports of HIV-infected
pregnant women, hospital discharge summaries, and matches of HIV-infected women with
vital statistics birth registry data. Health departments in designated areas collect demographic
and clinical information on HIV-infected mothers including engagement in prenatal care, HIV
testing history, and use of ART mainly by means of chart abstraction.
We performed a retrospective analysis using the Philadelphia EPS, which includes all HIV-
infected women who delivered a live infant in Philadelphia and the surrounding counties
between January 2005 and May 2013. EPS was merged with the Enhanced HIV/AIDS Report-
ing System (eHARS). eHARS is a surveillance system of all reported HIV/AIDS cases in Penn-
sylvania that is conducted by the Pennsylvania Department of Public Health in cooperation
with the Philadelphia Department of Public Health. eHARS contains demographic and clinical
information of HIV-infected individuals including all HIV VL.
Outcome Variables
Our outcomes of interest were receipt of ART during pregnancy and viral suppression at deliv-
ery. Receipt of ART was defined as having at least three antiretrovirals prescribed at any point
during the pregnancy. HIV viral suppression was defined as having an HIV VL 400 copies/
ml at the time closest to the delivery date up to 30 days postpartum. The cut-off value of 400
copies/ml was used in the early years of our study period and applied to the entire cohort for
consistency. When missing, the VLs were supplemented with eHARS VLs.
Independent Variables
Demographic variables included age, race/ethnicity, and health insurance status. Age was clas-
sified as 16–24, 25–34, and35 years; race/ethnicity was grouped as white non-Hispanic,
black non-Hispanic, Hispanic/Latino, and other. Health insurance status was classified as pub-
lic, private, or uninsured. Public insurance included patients on Medicaid, Medicare, and other
state funding. Use of illicit drugs during pregnancy was determined through medical and social
work chart review and toxicology results. Engagement in prenatal care was assessed using a
widely accepted, validated index of adequacy of prenatal care—the Kessner Institute of Medi-
cine Index. This measure takes into account timing of entry in prenatal care, number of prena-
tal visits, and gestational age at delivery. [22] The timing of HIV diagnosis was classified as
before or during pregnancy. Year of infant delivery was grouped in three evenly split time peri-
ods: 2005–2007, 2008–2010 and 2011–2013. In each time period, major revisions in ART treat-
ment took place: in 2007, guidelines revisions called for initiation of ART when the CD4
was< 350 cell/μl; in 2009, the CD4 count treatment cut off level moved to 500 and in 2012,
ART was to be initiated among all HIV-infected individuals, regardless of CD4 count.
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Statistical Analysis
The analysis included each delivery and was therefore performed at the mother-to-child pair
level. We first evaluated the progression of all demographic, clinical and outcome variables
over the previously described time periods: 2005–2007, 2008–2010 and 2011–2013. We then
compared sociodemographic and clinical differences in the proportion of mother-to-child
pairs on ART (versus not) during pregnancy and virally suppressed (versus not) at delivery
using Pearson χ2 tests. Multivariable logistic regression was used to estimate the association
between sociodemographic (age, race, insurance status, drug use) and clinical (adequacy of pre-
natal care and timing of HIV diagnosis) factors and the two outcomes, receipt of ART during
pregnancy and viral suppression at delivery. STATA 12 (StataCorp, College Station, TX) was
used for data analysis.
The data generated for this study were subjected to the same security and confidentiality
requirements as the national EPS. This includes adherence to CDC guidelines for the security
and confidentiality of HIV/AIDS surveillance data. IRB exemption was granted by the Phila-
delphia Department of Public Health. Written consent was not obtained for this study. Patient
records were anonymized and de-identified prior to data analysis.
Results
Our cohort included 836 mother-to-child pairs involving 656 HIV-infected women between
2005 and 2013. There were 12% missing VLs. Missing VLs were grouped with the unsup-
pressed (HIV VL> 400 copies/ml) since a sensitivity analysis after exclusion of the missing
VLs did not substantially alter findings of our data analysis. The majority (82%) of VLs were
obtained during the second or third trimesters with a mean of 8 weeks (SD 9.2) before delivery
(the 50th percentile was -5 weeks).
Of all the mother-to-child pairs, 51% were between 25 and 34 years old, 79% were black
non-Hispanic, 78% were publically insured, and 23% used illicit drugs during pregnancy
(Table 1). In total, 39%, 38%, and 23% of mother-to-child pairs were adequately, intermedi-
ately, and inadequately engaged in prenatal care, respectively. Three quarters were diagnosed
with HIV before pregnancy and a quarter were diagnosed during pregnancy. Most mother-to-
child pairs (85%) received ART during pregnancy and only 52% achieved viral suppression at
delivery (Table 1). Among the 836 mother-to-child pairs, 18 infants contracted HIV resulting
in a MTCT rate of 2.1%.
The age, race/ethnicity and drug use among mother-to-child pairs did not vary over time.
The uninsured increased as the number of mother-to-child pairs publically insured decreased.
Adequacy of prenatal care and the timing of HIV diagnosis improved as more mother-to-
child pairs received less inadequate care and more intermediate care and more HIV diagnoses
were established before as opposed to during pregnancy (Table 1). Receipt of ART and viral
suppression significantly improved as well: 80% of mother-to-child pairs received ART in
2005–2007, that proportion increased to 92% in 2011–2013; 36% of mother-to-child pairs
were suppressed at delivery in 2005–2007 as opposed to 69% in 2011–2013. In our multivariate
analysis, pairs with an infant delivery in 2011–2013 were 3 times more likely to receive ART
and 4 times more likely to achieve suppression compared to pairs with an infant delivery in
2005–2007.
Mother-to-child pairs receiving and not receiving ART during pregnancy were similar in
age, race/ethnicity, and health insurance status (S1 Table). However, pairs on ART were less
likely to use illicit drugs during pregnancy (20% vs. 40%), more likely to engage in adequate
prenatal care (44% vs. 12%), and more likely to be diagnosed with HIV before pregnancy (79%
vs. 53%) than the pairs not on ART. Other than drug use, demographic factors were similar
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among those who achieved suppression at delivery versus those who did. Mother-to-child
pairs with a suppressed VL at delivery were more likely to have received adequate prenatal care
(45% vs. 32%) and have an HIV diagnosis before pregnancy (80% vs. 69%) compared to pairs
with unsuppressed VL at delivery.
Outcomes differed by timing of HIV diagnosis and engagement in prenatal care. Overall,
89% of mother-to-child pairs diagnosed with HIV before pregnancy received ART and 56%
achieved viral suppression at delivery. In contrast, 71% of pairs diagnosed with HIV during
pregnancy received ART and only 42% achieved viral suppression at delivery (Fig 1). When
Table 1. Demographic, Behavioral and Quality of Care Indicators among Pregnant Women Infected with HIV, Enhanced Perinatal Surveillance
Project, Philadelphia, 2005–2013.
Total, n (%) n = 836 2005–2007 2008–2010 2011–2013 p- value
Demographic/Behavioral
Age (years) 0.29
16–24 214 (25.6) 97 (28.0) 71 (23.1) 46 (25.3)
25–34 431 (51.6) 180 (52.0) 164 (53.2) 87 (47.8)
35 191 (22.8) 69 (20.0) 73 (23.7) 49 (26.9)
Race/Ethnicity 0.36
White, non-Hispanic 72 (8.6) 36 (10.4) 25(8.1) 11 (6.0)
Black, non-Hispanic 661 (79.1) 271 (78.3) 244 (79.2) 146 (80.2)
Hispanic or Latino 68 (8.1) 24 (6.9) 24 (7.8) 20 (11.0)
Other 35 (4.2) 15 (4.3) 15 (4.9) 5 (2.8)
Insurance <0.001
Public 650 (77.7) 290 (83.8) 232 (75.3) 128 (70.3)
Private 97 (11.6) 30 (8.7) 46 (14.9) 21 (11.5)
Uninsured 89 (10.6) 26 (7.5) 30 (9.7) 33 (18.1)
Drug Use During Pregnancy 0.67
Yes 191 (22.8) 76 (22.0) 69 (22.4) 46 (25.3)
No 645 (77.2) 270 (78.0) 239 (77.6) 136 (74.7)
Quality of Care Indicators
Adequacy of Prenatal Care† 0.006
Adequate 325 (38.9) 153 (44.2) 108 (35.1) 64 (35.2)
Intermediate 319 (38.2) 113 (32.7) 120 (39.0) 86 (47.2)
Inadequate 192 (23.0) 80 (23.1) 80 (26.0) 32 (17.6)
Timing of HIV Diagnosis 0.040
Before Pregnancy 625 (74.8) 243 (70.2) 241 (78.3) 141 (77.5)
During Pregnancy 211 (25.3) 103 (29.8) 67 (21.7) 41 (22.5)
Receipt of ART* 0.001
Yes 708 (84.7) 276 (79.8) 264 (85.7) 168 (92.3)
No 128 (15.3) 70 (20.2) 44 (14.3) 14 (7.7)
Viral Suppression at Delivery** <0.001
Yes 437 (52.3) 123 (35.6) 189 (61.4) 125 (68.7)
No 399 (47.7) 223 (64.4) 119 (38.6) 57 (31.3)
*ART = Antiretroviral Therapy. 708 (84.69%) mother-to-child pairs received ART during pregnancy.
**Viral suppression is deﬁned as having a VL(viral load) 400 copies/ml. 437 (52.27%) mother-to-child pairs achieved viral suppression at delivery. The
HIV VLs > 400 copies/ml include 12.44% missing HIV VL. The VLs were measured during pregnancy and up to 30 days postpartum.
† Adequacy of prenatal care was measured using the Kessner Index which takes in account timing of entry in prenatal care, the number of prenatal visits
and the gestational age at delivery. It is a validated measure of quality of prenatal care.
doi:10.1371/journal.pone.0132262.t001
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considering engagement in prenatal care, 95% of mother-to-child pairs with adequate care
engagement received ART and 60% achieved suppression. Corresponding proportions for
those intermediately and inadequately engaged in care were 93% and 56% and 53% and 32%,
respectively. In multivariate logistic regression models, engagement in prenatal care, timing of
HIV diagnosis, and infant birth year were significantly associated with both ART receipt and
viral suppression (Table 2). Mother-to-child pairs with inadequate prenatal care were less likely
to receive ART (AOR 0.06, 95% CI 0.03–0.11) and achieve viral suppression (AOR 0.31, 95%
CI 0.20–0.47) compared to those with adequate prenatal care. The likelihood of ART receipt
(AOR 0.39, 95% CI 0.25–0.61) and viral suppression (AOR 0.70, 95% CI 0.49–1.00) were lower
among mother-to-child pairs diagnosed with HIV during compared to before pregnancy.
Fig 1. Receipt of ART and Viral Suppression by A) Timing of HIV Diagnosis and B) Quality of Prenatal Care.
Adequacy of prenatal care was measured using the Kessner Index, a validated index of quality of prenatal
care which takes into account timing of entry in prenatal care, the number of prenatal visits and gestational
age at infant delivery; ART: antiretroviral; VL: viral load; dx: diagnosis.
doi:10.1371/journal.pone.0132262.g001
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Discussion
Our study is the first to use population based data to evaluate viral suppression rates of HIV-
infected pregnant women at delivery. Our findings have significant public health implications
for HIV, maternal and fetal health and thus provide a platform for future public health inter-
ventions. We found that 85% of mother-to-child pairs received ART during pregnancy but
only half achieved viral suppression at delivery. These viral suppression rates, although lower
than those reported elsewhere, [23–25] were collected in undisturbed, real life settings, and
directly reflect patterns of HIV suppression at delivery from a cohort representative of HIV-
infected pregnant women in a major U.S city. Factors associated with both receipt of ART and
viral suppression included timing of HIV diagnosis, quality of prenatal care and birth year.
In the Women and Infants Transmission Study (WITS), women had a viral suppression
rate of 68% at delivery; [23, 26] however, WITS is by design a research cohort where women
are actively enrolled and followed up upon with use of detailed medical and behavioral ques-
tionnaires. In addition, the study was conducted a decade ago (between 1998 and 2005); the
choice and availability of ART in the general population and among pregnant women, as well
as policies relating to HIV care, have evolved since then. Data from a recent analysis of the
International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group, 2002–
2011, reported that 13% of women who newly initiated ART during pregnancy had a detectable
VL at delivery. Women with no reported use of ART during pregnancy and those with ART
use prior to conception were excluded from the study[25]. Our analysis of population based
Table 2. Demographic, Behavioral and Clinical Factors associated with 1) ART Prescription and 2)
HIV Viral Suppression using Multivariate Logistic Regression.
Receipt of ART Viral Suppression
AOR (95% CI) AOR (95% CI)
16–24 (years) - -
25–34 0.48 (0.26–0.88) 0.98 (0.68–1.44)
 35 0.42 (0.20–0.87) 0.88 (0.56–1.40)
White, non-Hispanic - -
Black, non-Hispanic 0.48 (0.19–1.20) 0.74 (0.44–1.25)
Hispanic or Latino 0.33 (0.10–1.10) 0.72 (0.35–1.51)
Other 0.91 (0.22–3.75) 0.62 (0.23–1.71)
Public Insurance - -
Private Insurance 0.82 (0.37–1.80) 1.18 (0.71–1.96)
Uninsured 1.19 (0.54–2.60) 1.34 (0.78–2.31)
Illicit Drug Use, No - -
Illicit Drug Use, Yes 0.75 (0.45–1.28) 0.77 (0.53–1.13)
Adequate Prenatal Care - -
Intermediate Prenatal Care 0.62 (0.31–1.24) 0.74 (0.53–1.04)
Inadequate Prenatal Care 0.06 (0.03–0.11) 0.31 (0.20–0.47)
HIV Dx Before Pregnancy - -
HIV Dx During Pregnancy 0.39 (0.25–0.61) 0.70 (0.49–1.00)
Year of Delivery 2005–2007 - -
Year of Delivery 2008–2010 2.07 (1.23–3.48) 3.19 (2.27–4.49)
Year of Delivery 2011–2013 3.60 (1.82–7.14) 4.13 (2.75–6.20)
ART—antiretroviral; Dx—diagnosis; CI—conﬁdence interval; bold face font, statistically signiﬁcant
p < 0.001.
doi:10.1371/journal.pone.0132262.t002
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data allowed the inclusion of women in various clinical settings (university associated clinics,
private practice or community health centers) and showed that the rate of viral suppression
among HIV-infected pregnant is much lower than anticipated. This finding has direct implica-
tions on maternal and fetal health since maternal immunosuppression is closely linked to
maternal and fetal morbidity. Beyond the goal of reducing mother-to-child transmission, our
findings call for additional public health interventions to improve the quality of HIV care in
the perinatal period.
Our study adds to the existing literature by identifying women at high risk of virological fail-
ure at delivery. In our univariate analysis, women with active drug use, with inadequate prenatal
care, with a late HIV diagnosis (i.e. HIV diagnosis made during instead of before pregnancy)
were less likely to receive ART and be suppressed at delivery. Our findings are in accordance
with prior data showing that late initiation of ART and delayed entry into prenatal care were sig-
nificantly associated with a detectable viral load at delivery[25]. Women with poor engagement
in prenatal care are at high-risk of clinical failure during the perinatal periods and should be
identified as such during routine care. In addition, measures to optimize viral suppression at
delivery should be applied. The role of directly observed therapy and raltegravir intensification
has been shown to be beneficial in other populations [27, 28] and should be evaluated among
HIV-infected women with poor engagement in prenatal care and poor adherence to ART.
In our multivariate analysis, an HIV diagnosis made during pregnancy was strongly associ-
ated with poor receipt of ART and viral suppression. This is in contrast with results from the
IMPAACT Group showing that a slightly larger proportion of women diagnosed with HIV
before pregnancy had detectable VL at delivery compared to women diagnosed with HIV dur-
ing pregnancy (16% versus 11%, p = 0.05). Timing of HIV diagnosis was not included in their
multivariate logistic regression model, it’s unclear if this relationship would remain after
adjustment of confounders[25]. An HIV diagnosis made before pregnancy allows time for
patients and providers to work through treatment decisions and life adjustments. This process
is even more important for women with repeated pregnancies as data show that multiparous
women are less likely to adhere to ART because, among other things, the increased child care
burden.[25, 29] The implementation of opt-out HIV testing in all healthcare settings as advo-
cated by the CDC and the US Preventive Services Task Force is likely to result in early diagnosis
of HIV among women of child bearing age. HIV testing needs to also be performed outside of
traditional healthcare settings to reach women who are out of care and who are at risk of
unplanned pregnancies, particularly those who exchange money for drugs or sex. Women
diagnosed with HIV during pregnancy should receive supportive services tailored to their emo-
tional needs (particularly with HIV acceptance and disclosure) and clinical needs in order to
improve their health outcomes.
Women who received inadequate prenatal care were less likely to adhere to therapy and
achieve viral suppression at delivery. Surely, adherence to prenatal visits is a surrogate marker
of women’s motivation to achieve good health outcomes for themselves and their infants and
facilitates repeated assessments of HIV disease. According to the American Congress of Obste-
tricians and Gynecologists prenatal care guidelines,[30] HIV infected women should engage in
care during their first trimester, have an average of 11 prenatal visits during pregnancy and
have frequent viral load monitoring if adherence to ART is a concern. Studies have shown that
poor engagement in prenatal care predict maternal loss to follow-up post-partum and nega-
tively affect MTCT rates.[31, 32] Possible solutions to improve the quality of prenatal care
include identifying women with repeated missed visits and use of interventions which have
been proven to work in other settings such as the peer-coaching,[33–35] financial incentives,
[36, 37] and the involvement of case management,[38, 39] particularly for women who are
homeless or suffer from mental health and substance abuse.
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Other documented barriers to ART adherence and prenatal care not measured in this study
include stigma,[19, 40, 41] socioeconomic stressors, [19, 41–43] lack of social support,[20, 41,
42] and mental health.[20, 44] Qualitative studies are needed to understand how socio-
cognitive and socio-contextual factors influence women’s decision making vis-à-vis HIV care
engagement during pregnancy. Health system factors, such as models of HIV care delivery
where HIV and obstetrical care and offered at the same site versus separate sites, and their asso-
ciation with virological failure at delivery need to be evaluated. For optimal maternal and fetal
health outcomes, HIV, obstetrical and pediatric care need to be closely coordinated.
Despite overall low viral suppression rates, we found that ART use and viral suppression
significantly improved over time. During our study period, the Department of Health and
Human Services guidelines for initiation of ART in the general population changed multiple
times, and in each instance the initiation of ART was recommended at higher CD4 counts.[45]
The improved ART receipt and viral suppression rates observed during our study period could
be related to these guideline revisions as well as other unmeasured factors.
The strengths of our study include its sample size. We captured 836 deliveries over a 9 year
period. Because of mandatory reporting of HIV infected mothers and their perinatally exposed
infants, we were able to capture the vast majority of women with HIV who had a delivery in
Philadelphia and its surrounding counties. The Philadelphia Department of Public Health case
ascertainment is estimated to be 98.5% using CDC supplied programs. Our analysis was also
done using real life data in undisturbed clinical settings and is representative of the population
studied. The limitations include shortcomings associated with secondary data analysis. Since
the majority of variables other than laboratory values were obtained from chart abstraction, we
depend on the quality of documentation from the providers during the prenatal visits and hos-
pitalizations. This is particularly relevant to the ART receipt variable since we had no comple-
mentary pharmacy data available to verify receipt of ART. Important variables, such as a
diagnosis of mental health, intimate partner violence and planned versus unplanned pregnancy
were not captured in our database. We would caution against extrapolations of our findings to
populations in cities with differences in local resources, demography and behavioral trends
during pregnancy.
In conclusion, we found that a large proportion of pregnant women infected with HIV failed
to achieve viral suppression at delivery. Even though viral suppression improved over the time
period of the study, women diagnosed with HIV during pregnancy and who received inade-
quate prenatal care were significantly less likely to be suppressed at delivery. These women,
because of their risk for poor HIV outcomes, should be seen as a vulnerable group in which
women-centered, culturally sensitive outreach measures should be implemented as early as
possible during pregnancy in order to avoid complications related to uncontrolled HIV disease
for the mother and the infant.
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